News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Post Conference Perspectives: Immunotherapy Combinations for Unresectable HCC

EP. 1: The Impact of Liver Pathobiology on HCC Treatment Approach

January 31st 2020

EP. 2: IMbrave150 Phase III Design, Results, and Practical Implications

January 31st 2020

EP. 3: The COSMIC-312 Phase III and Other Notable Trials

January 31st 2020

EP. 4: Challenges With Novel Treatment Strategies

January 31st 2020

EP. 5: Immunotherapy in Unresectable HCC

January 31st 2020

EP. 6: IMbrave150 in Unresectable HCC

January 31st 2020

EP. 7: Emerging I-O Combination Trials in Unresectable HCC

January 31st 2020

EP. 8: Sequencing With I-O Combinations in Unresectable HCC

January 31st 2020

EP. 9: Treating Unresectable HCC in the Community

January 31st 2020

EP. 10: Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

January 31st 2020

EP. 11: FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

January 31st 2020

Trending on OncLive

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL